A
AZTR
vs
S&P 500
S&P 500
Over the past 12 months, AZTR has underperformed S&P 500, delivering a return of -93% compared to the S&P 500's +17% growth.
Stocks Performance
AZTR vs S&P 500
Performance Gap
AZTR vs S&P 500
Performance By Year
AZTR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Azitra Inc
Glance View
Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
